Home > Tests and Treatments > Visual acuity test

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

A.D.A.M. Medical Encyclopedia [Internet]. Atlanta (GA): A.D.A.M.; 2013.

A.D.A.M. Medical Encyclopedia.

Visual acuity test

Eye test - acuity; Vision test - acuity; Snellen test

Last reviewed: February 7, 2013.

The visual acuity test is used to determine the smallest letters you can read on a standardized chart (Snellen chart) or a card held 20 feet away. Special charts are used when testing at distances shorter than 20 feet.

How the test is performed

This test may be done in a health care provider's office, a school, a workplace, or elsewhere.

You will be asked to remove your glasses or contact lenses and stand or sit 20 feet from the eye chart. You will keep both eyes open.

You will be asked to cover one eye with the palm of your hand, a piece of paper, or a small paddle while you read out loud the smallest line of letters you can see on the chart. Numbers or pictures are used for people who cannot read, especially children.

If you are not sure of the letter, you may guess. This test is done on each eye, one at a time. If needed, it is repeated while you wear your glasses or contacts. You may also be asked to read letters or numbers from a card held 14 inches from your face. This will test your near vision.

How to prepare for the test

No special preparation is necessary for this test.

How the test will feel

There is no discomfort.

Why the test is performed

The visual acuity test is a routine part of an eye examination or general physical examination, particularly if there is a change in vision or a problem with vision.

In children, the test is performed to screen for vision problems. Vision problems in young children can often be corrected or improved. Undetected or untreated problems may lead to permanent vision damage.

There are other ways to check vision in very young children, or in people who do not know their letters or numbers.

Normal Values

Visual acuity is expressed as a fraction.

  • The top number refers to the distance you stand from the chart. This is usually 20 feet.
  • The bottom number indicates the distance at which a person with normal eyesight could read the same line you correctly read.

For example, 20/20 is considered normal. 20/40 indicates that the line you correctly read at 20 feet away can be read by a person with normal vision from 40 feet away.

Even if you miss one or two letters on the smallest line you can read, you are still considered to have vision equal to that line.

What abnormal results mean

Abnormal results may be a sign that you need glasses or contacts. Or it may mean that you have an eye condition that needs further evaluation by a health care provider.

What the risks are

There are no risks.

References

  1. American Academy of Ophthalmology Preferred Practice Patterns Committee. Preferred Practice Pattern Guidelines. Comprehensive Adult Medical Eye Evaluation. Available at http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=64e9df91-dd10-4317-8142-6a87eee7f517. Accessed February 26, 2013.
  2. Colenbrander A. Measuring vision and vision loss. In: Tasman W, Jaeger EA, eds. Duane's Ophthalmology. 2013 ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012:vol 5, chap 51.
  3. Miller D, Schor P, Magnante P. Optics of the normal eye. In: Yanoff M, Duker JS, eds. Ophthalmology. 3rd ed. Philadelphia, PA: Elsevier Mosby; 2008:chap 2.6.

Review Date: 2/7/2013.

Reviewed by: Franklin W. Lusby, MD, Ophthalmologist, Lusby Vision Institute, La Jolla, California. Also reviewed by A.D.A.M. Health Solutions, Ebix, Inc., Editorial Team: David Zieve, MD, MHA, Bethanne Black, Stephanie Slon, and Nissi Wang.

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only — they do not constitute endorsementscof those other sites. © 1997–2011 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

Copyright © 2013, A.D.A.M., Inc.

What works?

  • There is no evidence that MPACs (PBT1 or PBT2) are of benefit in Alzheimer's dementiaThere is no evidence that MPACs (PBT1 or PBT2) are of benefit in Alzheimer's dementia
    The protein amyloid‐β (Aß) is strongly implicated in the development of Alzheimer's dementia, where it aggregates in clumps causing damage and death of brain cells. This clumping is encouraged by copper and zinc (metal ions) in the brain. Metal protein attenuating compounds (MPACS) bind strongly to copper and zinc (this is known as chelation), both preventing the clumping together of Aß and promoting processes which may cause it to dissolve and so be cleared from brain cells. Therefore MPACS may be a potential therapy for Alzheimer's dementia. Two different types of MPAC have been used in clinical trials and the drugs are known as PBT1 and PBT2. The trial of PBT1 compared with placebo (in 36 patients) showed no statistically significant difference in cognition or memory between the active treatment and placebo groups at 36 weeks. We therefore conclude that there is no current evidence that treatment with clioquinol (PBT1) has any significant effect on cognition and in particular memory (as measured by the ADAS‐Cog scale) in patients with Alzheimer's dementia. This drug has now been withdrawn from development. The trial of PBT2 showed it was safe after 12 weeks of treatment but demonstrated no overall significant effect on cognition or memory.
See all (3) ...

Figures

  • Eye.
    Visual acuity test.
    Normal, nearsightedness, and farsightedness.

In the news...

  • Image of womenNo proof found that depression is 'contagious'
    22 April 2013
    'Can you catch depression?', the Mail Online website asks on the strength of new US research into the concept of 'cognitive vulnerability'. Cognitive vulnerability is where unhelpful patterns of thin...
more...

MedlinePlus.gov links to free, reliable, up-to-date health information from the National Institutes of Health (NIH) and other trusted health organizations.

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk